Objective To investigate the effect of high-voltage electrostatic therapy on chronic migraine. Methods 86 cases who met inclusioncriteria were randomly divided into two groups: high-voltage group (n=43) was treated with high-voltage therapeutic device for 20d. Control group (n=43) was blank control. The recovered cases were followed up for 4 weeks after cessation of treatment. They were assessedwith McGill Pain Questionnaire (MPQ), and their results of laboratory tests were recorded before and after treatment. The data set analyzedincluded Intention-To-Treat, and per protocol. Results The differences between 2 groups were statistically significant in Pain RatingIndex, Visual Analog Score and Present Pain Intensity after treatment (P<0.05). 6 patients in the treatment group and 1 patient in the controlgroup recovered. During the 4-week follow-up, 1 case recured in each group, the intensity of pain was not statistically significant. There wasno difference in the laboratory indice of blood, urine, stool routine, liver and kidney function (ALT, BUN, Cr) and ECG in both groups beforeand after treatment. Conclusion The high-voltage electrostatic therapy is effective and safe on chronic migraine.

Low-frequency repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation method that has been used in the treatments of stroke patients. Our purpose was to investigate the effects of low-frequency rTMS on the hand motor function recovery for stroke patients. After searching from electronic database from January 1990 to April 2012, we collected randomized controlled trials explored the low-frequency rTMS effects on the hand motor function rehabilitation. A total of 7 comparisons (N = 216) from 5 articles were included in this study. We summarized the effect size by calculating the standardized mean difference (SMD). Summary of effect size (SES) indicated positive effects of low-frequency rTMS on the finger motor ability (SMD = 0.58) and hand function (SMD = -0.98). Few adverse effects occurred. The evidence showed that low-frequency rTMS could improve the paretic hand recovery after stroke.
Hand ; physiopathology ; Humans ; Recovery of Function ; Stroke ; therapy ; Transcranial Magnetic Stimulation

Objective To establish and validate a Nomogram for predicting the survival of patients with pediatric ependymoma based on SEER database. Methods We collected the clinicopathological data from 1975 to 2016 in the SEER database. Univariate and multivariate Cox proportional hazard regression models were used to identify potential predictors. A Nomogram was constructed to predict 5- and 10-year overall survival of patients with pediatric ependymoma. The consistency index (C-index), receiver operating characteristic curve and calibration curve were used to verify the discrimination and accuracy of the Nomogram. The decision curve analysis was performed to verify the clinical applicability of the Nomogram. Results A Nomogram model was established based on multivariate Cox proportional hazards model of training set. C-index values of the Nomogram were 0.713 (95%CI: 0.680-0.747) and 0.734 (95%CI: 0.681-0.787) in the training and validation sets, respectively. ROC curves also showed good discrimination in the training set. The calibration curves showed satisfactory consistency between Nomogram and ideal models. The decision curve analysis demonstrated the considerable clinical usefulness of the Nomogram. Conclusion The Nomogram model is constructed based on age at diagnosis, gender, race, primary tumor sites, tumor grade, surgery treatment and SEER registry to predict the survival of patients with pediatric ependymoma. It has good discrimination and accuracy degree, providing useful guidance to make more accurate and personalized survival prediction for patients in clinic.

ObjectiveTo investigate the efficacy and safety of artificial liver support therapy with an Evanure-4A selective membrane plasma separator and its influence on platelet count in the treatment of patients with acute-on-chronic liver failure （ACLF） patients with different platelet counts. MethodsA total of 302 patients with ACLF who were hospitalized in Department of Hepatology， Chengdu Public Health Clinical Medical Center， from January 2021 to May 2023， were enrolled， and according to the platelet count （PLT）， they were divided into group A （25×10⁹/L — 50×10⁹/L） with 101 patients， group B （51×10⁹/L — 80×10⁹/L） with 98 patients， and group C （81×10⁹/L — 100×10⁹/L） with 103 patients. In addition to medical treatment， all patients received different modes of artificial liver support therapy based on their conditions， including plasma perfusion combined with plasma exchange， double plasma molecular adsorption combined with plasma exchange， and bilirubin system adsorption combined with plasma exchange. The paired t-test was used for comparison of continuous data before and after treatment in each group； an analysis of variance was used for comparison between multiple groups， and the SNK-q test was used for further comparison between two groups； the chi-square test was used for comparison of categorical data between multiple groups. ResultsOf all 302 patients， 268 （88.74%） achieved varying degrees of improvement in clinical symptoms after artificial liver support therapy. After treatment， all three groups had varying degrees of reductions in alanine aminotransferase （t=14.755， 21.614， and 15.965， all P<0.001）， aspartate aminotransferase （t=11.491， 19.301， and 13.919， all P<0.001）， total bilirubin （t=19.182， 17.486， and 21.75， all P<0.001）， and international normalized ratio （INR） （t=3.497， 3.327， and 4.358， all P<0.05）. After artificial liver support therapy with an Evanure-4A selective membrane plasma separator， PLT in group A decreased from （37.73±6.27）×10⁹/L before treatment to （36.59±7.96）×10⁹/L after treatment， PLT in group B decreased from （66.97±7.64）×10⁹/L before treatment to （62.59±7.37）×10⁹/L after treatment， and PLT in group C decreased from （93.82±5.38）×10⁹/L before treatment to （85.99±12.49）×10⁹/L after treatment； groups B and C had significant reductions in PLT after treatment （t=12.993 and 8.240， both P<0.001）， but there was no significant difference in group A （P>0.05）. There was no significant difference in the incidence rate of adverse reactions during artificial liver support therapy between the three groups （P>0.05）. ConclusionArtificial liver support therapy can improve liver function and INR in patients with ACLF. The use of Evaure-4A selective membrane plasma separator during artificial liver support therapy has little influence on platelets， and it is safe in the treatment of ACLF patients with a significantly lower level of platelets.